Dr Reddy's is set to take total control of Perlecan Pharma, the novel R&D model

Dr Reddy had kicked off with funding support from venture capital investors ICICI Venture and Citigroup Venture Capital nearly three years ago. Dr Reddy’s will clock 25% growth this year | More India business stories The Hyderabad-based pharma major will pay $18 million in all for the 43% equity each that the two investors hold in Perlecan.